Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting

Next Previous
Trial Profile

A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab biosimilar Amgen (Primary) ; Nivolumab
  • Indications Malignant melanoma
  • Focus Pharmacokinetics
  • Sponsors Amgen

Most Recent Events

  • 27 Oct 2025 Planned End Date changed from 30 Nov 2025 to 31 Oct 2025.
  • 27 Oct 2025 Planned primary completion date changed from 4 Oct 2025 to 31 Oct 2025.
  • 04 Feb 2025 According to an Amgen media release, Data readout is anticipated in H2 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top